Tanvex BioPharma, Inc.
6541
Rank in Stocks
#16053
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a... Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
Share Price
$0.86880707
Last synced: 2026-11-10
Market Cap
$230.23M
Change (1 day)
-2.06%
Change (1 year)
-50.77%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tanvex BioPharma, Inc. (6541)
Category
Healthcare
Operating Margin for Tanvex BioPharma, Inc. (6541)
Operating Margin as of November 2026 TTM: -217.02%
According to Tanvex BioPharma, Inc.'s latest financial reports, its current operating margin (TTM) is -217.02%. At the end of 2025 the company had an operating margin of -346.21%.
Operating Margin history for Tanvex BioPharma, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -217.02% | -37.32% |
| 2025 | -346.21% | -91.15% |
| 2024 | -3,912.40% | 14.37% |
| 2023 | -3,420.80% | -51.69% |
| 2022 | -7,080.82% | -74.43% |
| 2021 | -27,690.84% | -96.02% |
| 2020 | -695,214.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.18% |
US
|
|
| -149.01% | -99.31% |
US
|
|
| 25.57% | -100.12% |
AU
|
|
| 31.23% | -100.14% |
BE
|
|
| 29.35% | -100.14% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Tanvex BioPharma, Inc.'s operating margin
What is Tanvex BioPharma, Inc.'s operating margin?
Tanvex BioPharma, Inc.'s operating margin is -217.02%, as of Nov 2026.
What was Tanvex BioPharma, Inc.'s operating margin in 2025?
In 2025, Tanvex BioPharma, Inc.'s operating margin was -346.21%, compared with -3,912.40% in 2024.
How has Tanvex BioPharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Tanvex BioPharma, Inc.'s operating margin was highest in 2025 (-346.21%) and lowest in 2020 (-695,214.00%).
How does Tanvex BioPharma, Inc.'s operating margin compare with similar companies?
Tanvex BioPharma, Inc.'s operating margin (-217.02%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.